Zimmer Biomet to Acquire iovera° Device from Pacira BioSciences for $140M

Zimmer Biomet Holdings (NYSE: ZBH) announced an agreement to acquire the iovera° device from Pacira BioSciences for $140 million, adding a targeted cryoanalgesia technology to its musculoskeletal portfolio. The deal includes potential milestone payments that may be achieved through December 31, 2031. ZBH shares fell 5.64% on Tuesday, June 30, 2026, closing at $86.09.

Deal Terms

• Purchase price: $140 million upfront for the iovera° device from Pacira BioSciences
• Milestone structure: Additional payments tied to performance milestones achievable through December 31, 2031
• Seller: Pacira BioSciences, a specialty pharmaceutical and medical device company
• Asset: The iovera° device, a targeted cryoanalgesia system used to treat pain

Why It Matters

The iovera° device delivers focused cold therapy to peripheral nerves to provide localized pain relief, a capability that fits alongside Zimmer Biomet's existing joint reconstruction and surgical portfolio. Acquiring the device from Pacira gives Zimmer Biomet direct ownership of the technology and its commercial infrastructure rather than relying on a distribution or licensing arrangement.

The milestone payment structure, with obligations potentially extending through the end of 2031, means Zimmer Biomet's total consideration will depend on commercial performance over a multi-year horizon. This contingent structure limits upfront capital exposure while aligning the seller's incentives with post-close adoption of the device across Zimmer Biomet's customer base.

Wall Street View

Analyst sentiment on ZBH heading into the announcement leaned cautious, with the most recent consensus (as of June 1, 2026) showing 20 Hold ratings alongside 8 Buy and 4 Strong Buy recommendations, and 2 Sell ratings. The distribution reflects a divided view on the company's near-term trajectory, and no updated price targets tied directly to this transaction were available in current data.

Investor Takeaway

Zimmer Biomet's $140 million acquisition of the iovera° device represents a targeted portfolio addition with a contingent payment tail through 2031, giving the company exposure to cryoanalgesia technology within its core musculoskeletal market. The deal's structure caps immediate cash outlay while tying future payments to commercial execution, a design that distributes risk across the milestone period. Investors will be watching whether the iovera° device can generate meaningful incremental revenue within Zimmer Biomet's existing sales channels.